From Our Partners

Busting the PoseBusters v3: AI Docking Software ArtiDock Beats Industry’s State of the Art in Speed and Accuracy

We at Receptor.AI are excited to present the next important milestone in the development of our next-generation AI docking model, …

Continue ›››

AI Breaches the Barrier Towards Better CNS Drug Discovery

The sphere of oncology continues to grapple with the complex nature of brain and central nervous system (CNS) tumors. Data …

Continue ›››

ArtiDock from Receptor.AI: Next-generation AI Docking That Beats DiffDock and AlphaFold-latest

Receptor.AI has announced ArtiDock, the best-in-class model for “AI docking," which predicts the binding poses of small molecule ligands in protein …

Continue ›››

How to Discover a Preclinical Drug Candidate in Two Years

Recent advances in artificial intelligence (AI) has played a pivotal role in optimizing the small-molecule synthesis, standardization, scalability and CRO-based …

Continue ›››

How Syntekabio’s Supercomputing Enables AI-driven Drug Discovery

What is "supercomputing"? It refers to processing a massive quantity of complex data-intensive and computation-heavy problems often found in scientific …

Continue ›››

The Power of STB CLOUD in Remote AI Drug Discovery

STB CLOUD is Syntekabio’s latest cloud-based, fully automated AI platform. It’s designed for developers to engage in their drug discovery …

Continue ›››

Democratizing Early Drug Discovery through Artificial Intelligence: Interview with Syntekabio CEO Jongsun Jung

Before the age of modern drug discovery, the pharmaceutical industry had been plagued with uncertainty and processing challenges, including the …

Continue ›››

Powering Cancer Drug Discovery and Development Using the Artificial Intelligence and Machine Learning Platform RADR®

Introduction Glioblastomas (GBM) are devastating brain tumors and rank as one of the most aggressive human cancers with a median …

Continue ›››

Using End-to-End Wet Lab Automation Combined with Machine Learning to Industrialize Drug Discovery

Arctoris is driven by a relentless pursuit to make drug discovery better. An industry where bringing a single drug to …

Continue ›››

Identifying High Impact Tissue Sparing E3 Ligases and Their Binders

There are many drug target classes for which unwanted on-target pharmacology limits clinical application. Understanding E3 tissue expression across both …

Continue ›››

QUAISAR Computational Platform for Designing Targeted Protein Degraders

A key step in the targeted protein degradation (TPD) process is the formation of an induced proximity complex, where a …

Continue ›››

Application of AI-driven Xanthos Platform for Designing Protein Degraders

In contrast to the discovery of "traditional drugs" such as small molecule inhibitors and most biologics, the development of protein …

Continue ›››